
Sign up to save your podcasts
Or
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TFB865. CME/MOC/AAPA/IPCE credit will be available until April 27, 2026.
Unleashing Immunotherapy Against Resectable Melanoma: The Surgeon-Oncologist Alliance for Delivering Adjuvant and Neoadjuvant Therapy
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported through educational grants from Bristol Myers Squibb and Merck & Co., Inc., Rahway, NJ, USA.
Disclosure information is available at the beginning of the video presentation.
4.3
99 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TFB865. CME/MOC/AAPA/IPCE credit will be available until April 27, 2026.
Unleashing Immunotherapy Against Resectable Melanoma: The Surgeon-Oncologist Alliance for Delivering Adjuvant and Neoadjuvant Therapy
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported through educational grants from Bristol Myers Squibb and Merck & Co., Inc., Rahway, NJ, USA.
Disclosure information is available at the beginning of the video presentation.
128 Listeners
6 Listeners
31 Listeners
3 Listeners
3 Listeners
10 Listeners
5 Listeners
28 Listeners
9 Listeners
3 Listeners
2 Listeners
5 Listeners
3 Listeners
3 Listeners
5 Listeners
5 Listeners
2 Listeners
0 Listeners
9 Listeners
318 Listeners
41 Listeners
2 Listeners
114 Listeners
2 Listeners
485 Listeners
56 Listeners
43 Listeners
21 Listeners
321 Listeners
53 Listeners
10 Listeners
166 Listeners
38 Listeners